Interrogating genomic and epigenomic data to understand prostate cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 2, 2012, Pages 186-196

  Kim, Jung ^a   Yu, Jindan ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Androgen receptor; EZH2; FoxA1; Gene fusion; Integrative genomics; Nucleosome positioning; Transcriptional regulation

Indexed keywords

ANDROGEN RECEPTOR; POLYCOMB GROUP PROTEIN; SERINE PROTEINASE; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR EZH2;

CANCER RESEARCH; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; GENE FUSION; GENOMICS; HIGH THROUGHPUT SCREENING; HISTONE MODIFICATION; HUMAN; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA INTERACTION; RECEPTOR BINDING; REVIEW; TRANSCRIPTION REGULATION;

EPIGENOMICS; GENE EXPRESSION; GENE FUSION; GENOMICS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTOME;

EID: 84862783103     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.12.003     Document Type: Review

References (144)

1. Jemal A., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(5):277-300.
2. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1(4):293-297.
3. Ruijter E., et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 1999, 20(1):22-45.
4. Kopper L., Timar J. Genomics of prostate cancer: is there anything to "translate"?. Pathol. Oncol. Res. 2005, 11(4):197-203.
5. Golub T.R., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537.
6. Schena M., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270(5235):467-470.
7. Hughes T.R., et al. Microarray analysis of RNA processing and modification. Methods Enzymol. 2006, 410:300-316.
8. Yu J., et al. Evaluation and optimization of procedures for target labeling and hybridization of cDNA microarrays. Mol. Vis. 2002, 8:130-137.
9. Dhanasekaran S.M., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412(6849):822-826.
10. Luo J., et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 2001, 61(12):4683-4688.
11. Welsh J.B., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61(16):5974-5978.
12. Kuefer R., et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am. J. Pathol. 2002, 161(3):841-848.
13. Luo J., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002, 62(8):2220-2226.
14. Zhou M., et al. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am. J. Surg. Pathol. 2002, 26(7):926-931.
15. Rubin M.A., et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002, 287(13):1662-1670.
16. Carswell B.M., et al. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy. Histopathology 2006, 48(6):668-673.
17. Varambally S., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419(6907):624-629.
18. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17(9):2613-2618.
19. Lapointe J., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(3):811-816.
20. Yu Y.P., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22(14):2790-2799.
21. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648.
22. Glinsky G.V., et al. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 2004, 113(6):913-923.
23. Stephenson A.J., et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 2005, 104(2):290-298.
24. Wang Q., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138(2):245-256.
25. Yu J., Cao Q., Yu J., Wu L., Dallol A., Li J., Latif F., Wu J., Chinnaiyan A.M. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 2010, 29(39):5370-5380.
26. Wang J., et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006, 66(17):8347-8351.
27. Soller M.J., et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006, 45(7):717-719.
28. Clark J., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26(18):2667-2673.
29. Soda M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
30. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8(7):497-511.
31. Maher C.A., et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(30):12353-12358.
32. Rickman D.S., et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 2009, 69(7):2734-2738.
33. Tomlins S.A., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448(7153):595-599.
34. Tomlins S.A., et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011, 3(94):94ra72.
35. Barski A., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837.
36. Johnson D.S., et al. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007, 316(5830):1497-1502.
37. Mikkelsen T.S., et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448(7153):553-560.
38. Marguerat S., Wilhelm B.T., Bahler J. Next-generation sequencing: applications beyond genomes. Biochem. Soc. Trans. 2008, 36(Pt 5):1091-1096.
39. Sultan M., et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321(5891):956-960.
40. Shendure J., Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 2008, 26(10):1135-1145.
41. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11(10):685-696.
42. Maher C.A., et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458(7234):97-101.
43. Palanisamy N., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 2010, 16(7):793-798.
44. Pflueger D., et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011, 21(1):56-67.
45. Mortazavi A., et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 2008, 5(7):621-628.
46. Marioni J.C., et al. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008, 18(9):1509-1517.
47. Wilhelm B.T., Landry J.R. RNA-Seq-quantitative measurement of expression through massively parallel RNA-sequencing. Methods 2009, 48(3):249-257.
48. Ng S.B., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009, 461(7261):272-276.
49. Kumar A., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(41):17087-17092.
50. Guttman M., et al. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat. Biotechnol. 2010, 28(5):503-510.
51. Prensner J.R., et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 2011, 29(8):742-749.
52. Xu G., et al. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One 2010, 5(11):e15519.
53. Orlando V. Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation. Trends Biochem. Sci. 2000, 25(3):99-104.
54. Buck M.J., Lieb J.D. ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. Genomics 2004, 83(3):349-360.
55. Lee T.I., Johnstone S.E., Young R.A. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 2006, 1(2):729-748.
56. Robertson G., et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 2007, 4(8):651-657.
57. Yu J., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007, 67(22):10657-10663.
58. Gal-Yam E.N., et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(35):12979-12984.
59. Kirmizis A., et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004, 18(13):1592-1605.
60. Chen H., Tu S.W., Hsieh J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 2005, 280(23):22437-22444.
61. Min J., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010, 16(3):286-294.
62. Fujii S., et al. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 2008, 283(25):17324-17332.
63. Yu J., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17(5):443-454.
64. Takayama K., et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007, 26(30):4453-4463.
65. Massie C.E., et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 2007, 8(9):871-878.
66. Bolton E.C., et al. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21(16):2005-2017.
67. Wang Q., et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27(3):380-392.
68. Lin B., et al. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One 2009, 4(8):e6589.
69. Wang D., et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011, 474(7351):390-394.
70. Sahu B., et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011, 30(19):3962-3976.
71. Shang Y., Myers M., Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 2002, 9(3):601-610.
72. Wang Q., Carroll J.S., Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 2005, 19(5):631-642.
73. Lupien M., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132(6):958-970.
74. Robinson J.L., et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011, 30(15):3019-3027.
75. Mehta R.J., et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res. Treat. 2011, [Epub ahead of print].
76. Augello M.A., Hickey T.E., Knudsen K.E. FOXA1: master of steroid receptor function in cancer. EMBO J. 2011, 30(19):3885-3894.
77. Zhang C., et al. Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011, 71(21):6738-6748.
78. Yu J., et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007, 12(5):419-431.
79. Cao Q., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27(58):7274-7284.
80. Kunderfranco P., et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 2010, 5(5):e10547.
81. Massie C.E., et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011, 30(13):2719-2733.
82. Grosse A., Bartsch S., Baniahmad A. Androgen receptor-mediated gene repression. Mol. Cell. Endocrinol. 2011, [Epub ahead of print].
83. Liu Y.N., et al. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol. Cell. Biol. 2008, 28(23):7096-7108.
84. Verras M., et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007, 67(3):967-975.
85. Song K., et al. DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol. Endocrinol. 2010, 24(10):2019-2029.
86. Lanzino M., et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. Nucleic Acids Res. 2010, 38(16):5351-5365.
87. Qi W., et al. Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-{beta}1 and CDK2 promoters in the prostate gland. J. Androl. 2011, 33(1):27-36.
88. Heckert L.L., Wilson E.M., Nilson J.H. Transcriptional repression of the alpha-subunit gene by androgen receptor occurs independently of DNA binding but requires the DNA-binding and ligand-binding domains of the receptor. Mol. Endocrinol. 1997, 11(10):1497-1506.
89. Baniwal S.K., et al. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol. Endocrinol. 2009, 23(8):1203-1214.
90. Cai C., et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011, 20(4):457-471.
91. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 2011, 11(10):726-734.
92. Perry A.S., et al. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol. 2010, 7(12):668-680.
93. Park J.Y. Promoter hypermethylation in prostate cancer. Cancer Control 2010, 17(4):245-255.
94. Nelson W.G., De Marzo A.M., Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009, 150(9):3991-4002.
95. Vasiljevic N., et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis. Markers 2011, 30(4):151-161.
96. Laird P.W. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 2010, 11(3):191-203.
97. Jacinto F.V., Ballestar E., Esteller M. Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques 2008, 44(1). 35, 37, 39 passim.
98. Meissner A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454(7205):766-770.
99. Kim J.H., et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011, 21(7):1028-1041.
100. Kobayashi Y., et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011, 21(7):1017-1027.
101. Hinoue T., et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2011, [Epub ahead of print].
102. Tahiliani M., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(5929):930-935.
103. Szulwach K.E., et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. 2011, 7(6):e1002154.
104. Wu H., et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011, 473(7347):389-393.
105. Ficz G., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473(7347):398-402.
106. Dawlaty M.M., et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9(2):166-175.
107. Ono R., et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62(14):4075-4080.
108. Langemeijer S.M., Aslanyan M.G., Jansen J.H. TET proteins in malignant hematopoiesis. Cell Cycle 2009, 8(24):4044-4048.
109. Li W., Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J. Nucleic Acids 2011, 2011:870726.
110. Haffner M.C., et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2(8):627-637.
111. Williams K., et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473(7347):343-348.
112. Song C.X., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 2011, 29(1):68-72.
113. Seligson D.B., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046):1262-1266.
114. Heintzman N.D., et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009, 459(7243):108-112.
115. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28(7):778-808.
116. Welsbie D.S., et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009, 69(3):958-966.
117. Metzger E., et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437(7057):436-439.
118. Shi Y., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7):941-953.
119. Lee M.G., et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005, 437(7057):432-435.
120. Metzger E., et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 2010, 464(7289):792-796.
121. Richmond T.J., Davey C.A. The structure of DNA in the nucleosome core. Nature 2003, 423(6936):145-150.
122. Segal E., et al. A genomic code for nucleosome positioning. Nature 2006, 442(7104):772-778.
123. Boeger H., et al. Nucleosomes unfold completely at a transcriptionally active promoter. Mol. Cell 2003, 11(6):1587-1598.
124. Shibata Y., Crawford G.E. Mapping regulatory elements by DNaseI hypersensitivity chip (DNase-Chip). Methods Mol. Biol. 2009, 556:177-190.
125. Boyle A.P., et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008, 132(2):311-322.
126. Giresi P.G., et al. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res. 2007, 17(6):877-885.
127. Eeckhoute J., et al. Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res. 2009, 19(3):372-380.
128. Zhang Y., et al. Identifying positioned nucleosomes with epigenetic marks in human from ChIP-Seq. BMC Genomics 2008, 9:537.
129. He H.H., et al. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 2010, 42(4):343-347.
130. Kaplan N., et al. The DNA-encoded nucleosome organization of a eukaryotic genome. Nature 2009, 458(7236):362-366.
131. Tillo D., et al. High nucleosome occupancy is encoded at human regulatory sequences. PLoS One 2010, 5(2):e9129.
132. Schones D.E., et al. Dynamic regulation of nucleosome positioning in the human genome. Cell 2008, 132(5):887-898.
133. Valouev A., et al. Determinants of nucleosome organization in primary human cells. Nature 2011, 474(7352):516-520.
134. Chen Z., et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011, 30(12):2405-2419.
135. Andreu-Vieyra C., et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol. Cell. Biol. 2011, 31(23):4648-4662.
136. Wu D., et al. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol. Metab. 2011, 22(12):474-480.
137. Lin C., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139(6):1069-1083.
138. Lieberman-Aiden E., et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009, 326(5950):289-293.
139. Umbarger M.A., et al. The three-dimensional architecture of a bacterial genome and its alteration by genetic perturbation. Mol. Cell 2011, 44(2):252-264.
140. Fullwood M.J., et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462(7269):58-64.
141. Li G., et al. ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol. 2010, 11(2):R22.
142. Liang R.Q., et al. An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucleic Acids Res. 2005, 33(2):e17.
143. Lu C., et al. Elucidation of the small RNA component of the transcriptome. Science 2005, 309(5740):1567-1569.
144. Fu Y., et al. The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet. 2008, 4(7):e1000138.